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Abstract The goal of therapy of rheumatoid arthritis is to
achieve a remission or at least low disease activity. TNF in-
hibitors induce high remission rates only in combination with
methotrexate, whereas the efficacy of tocilizumab is optimal
even as a monotherapy. In this article, the differing depen-
dence of the biological drugs on methotrexate is explained
from the viewpoint of an immunologist. A selective search
and evaluation of the literature was performed with regard to
the mode of action of TNF inhibitors, tocilizumab and meth-
otrexate in rheumatoid arthritis. Methotrexate primarily in-
hibits the activation and proliferation of lymphocytes. TNF
inhibitors suppress monocytes and myeloid dendritic cells,
and tocilizumab has a broader activity and is directed against
both the lymphoid as well as the myeloid compartment. In
view of the broad mode of action of tocilizumab, it can be
explained why this drug, in contrast to TNF inhibitors, is
acting optimally even in monotherapy.
Keywords Cytokines and inflammatorymediators .
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Background
Since the introduction of biologics into the treatment of rheu-
matoid arthritis (RA), patients’ symptoms have been signifi-
cantly reduced and the process of joint destruction markedly
decelerated. At present, about 15 % of RA patients in
Germany are treated with biologics. Five TNF inhibitors, to-
gether with tocilizumab and abatacept, are approved for use as
first-line biologics following failure of at least one or two
conventional disease-modifying anti-rheumatic drugs
(DMARDs). Earlier studies, e.g. the TEMPO trial for
etanercept [1] and the PREMIER trial for adalimumab [2],
showed that the TNF inhibitors in monotherapy are much less
effective than in combination with methotrexate. In contrast,
two studies (Charisma [3] and ACT-RAY [4]) demonstrated
for tocilizumab monotherapy near equivalence to similar effi-
cacy compared to tocilizumab in combination with methotrex-
ate. In the Adalimumab Actemra (ADACTA) trial,
adalimumab and tocilizumab were compared in RA patients
intolerant of methotrexate [5]. Tocilizumab was significantly
superior to adalimumab as assessed by various outcome pa-
rameters, including ACR20 response and reduction of
DAS28, CDAI and SDAI. In contrast to tocilizumab, TNF
inhibitors require combination therapy with methotrexate for
full effect. This article provides an overview of studies on the
mode of action of TNF inhibitors, tocilizumab and methotrex-
ate, and offers an explanation for the divergent dependency of
TNF inhibitors and tocilizumab on the combination with
methotrexate.
Pathophysiology of rheumatoid arthritis
The initiation of RA is facilitated by a genetic predisposition.
In addition, the probability of developing RA is influenced by
environmental factors such as smoking, alcohol and nutrition.
The autoimmune aspect of the disease begins many years
before overt arthritis occurs. In this ‘pre-arthritis’ phase, the
autoantibodies rheumatoid factor (RF) and anti-citrullinated
peptide/protein antibodies (ACPA) can usually be detected
[6]; however, even on biopsy, no inflammatory changes can
be found in the joint [7]. At present, it remains unclear where
T. Witte (*)
Clinic for Immunology and Rheumatology, Medical University of
Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
e-mail: Witte.Torsten@mh-hannover.de
Clin Rheumatol (2015) 34:629–634
DOI 10.1007/s10067-015-2861-x
the location of this pre-arthritis stage is. Candidates include
the respiratory system (since RA affects mainly smokers) and
the lymph nodes.
The joint inflammation, which usually starts after a long
period of pre-arthritis, has three main phases:
Adhesion and migration
At the initiation of arthritis, cells of the immune system move
into the joints. Arthritis is probably triggered by an
autoantigen in the joint. This autoantigen has not yet been
identified, and triggers are likely to vary from patient to pa-
tient. Initially, antigen-presenting cells in the joint loaded with
an autoantigen probably move to the central lymphatic organs
and activate Tcells there. They then migrate back to the joints,
along with circulating immune cells.
Activation/inflammation
Most of the lymphocytes in the synovial membrane comprise
CD4+ T-helper cells that are mainly part of the Th1 and pro-
inflammatory Th17 subsets [8, 9]. B cells and macrophages
are also present, as well as large numbers of neutrophil
granulocytes in the synovial fluid.
The cells of the immune system interact in the inflamed
joint and activate each other by cell-cell contact as well as
by the production of cytokines. The formation of cytokines
such as TNF-α and IL-6 at the site of inflammation leads to
activation of the endothelium cells in newly formed vessels
and to an increase in adhesion receptors such as intercellular
adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1) [10]. This further increases the adhe-
sion and finally migration of leucocytes and lymphocytes
from the blood into the inflamed joints [11].
Destruction of the joint
Fibroblast-like synovial cells are activated and produce colla-
genases (such as MMP-1, MMP-3 and MMP-13), which at-
tack the cartilage [12]. Then, an inflammatory pannus forms,
in which T and B lymphocytes, macrophages and dendritic
cells can be identified. The inflammatory tissue invades
deeper into the cartilage and finally the bone. Cytokines
formed in the ongoing inflammation, such as IL-6 and TNF-α,
activate chondro- and osteoclasts and thus further contribute
to the disintegration of bone and cartilage. Activated T cells
and IL-18-stimulated macrophages produce receptor activator
of nuclear factor kappa-B ligand (RANK-L), a substance that
also activates osteoclasts and promotes the disintegration of
bone. The inflamed tissue activates angioneogenesis with fac-
tors such as vascular endothelial growth factor (VEGF), pros-
taglandins, IL-8, ENA-78 or angiopoietin-1 [13, 14] in order
to be sufficiently supplied with blood. In spite of the active
formation of new vessels, blood supply to the inflammatory
tissue is critical, and the pO2 in the synovial fluid is always
markedly below that in the blood. Angioneogenesis therefore
is essential for the perpetuation of the inflammation [15].
Insights into the pathophysiology of RA have led to the
development and use of biologics. The mode of action of
classical DMARDs, and specifically that of methotrexate,
can now be at least partially explained.
Mode of action of methotrexate
Methotrexate (MTX) was first used in the treatment of RA in
1951 [16], but has only been widely prescribed since the
1980s. Methotrexate is a folic acid antagonist which reduces
the concentration of intracellular folinic acid needed for purine
and pyrimidine metabolism as well as for amino acid synthe-
sis. Methotrexate therefore has an anti-proliferative effect.
Based on recent studies, methotrexate also increases the ex-
tracellular concentration of the anti-inflammatory molecule
adenosine by dephosphorylation of adenine nucleotides, and
therefore has an anti-inflammatory effect in addition to its
anti-proliferative action.
Activation/inflammation
In patients with RA, methotrexate inhibits the proliferation of
cells and induces apoptosis (cell death) of activated cells. Both
mechanisms mainly affect the lymphocytes and also, to a less-
er degree, monocytes [17]. Methotrexate therefore reduces the
number of activated T lymphocytes (Fig. 1). The expression
of adhesion molecules such as ICAM-1 on T lymphocytes is
reduced, as well as the production of the cytokines IL-6,
TNF-α and GM-CSF by T lymphocytes [18]. The concentra-
tion of rheumatoid factor is also reduced in the process. In
contrast to its effect on T lymphocytes, methotrexate does
not substantially influence the cytokine production of mono-
cytes [18].
Methotrexate probably reduces the interaction of T lym-
phocytes and synovial fibroblasts by reduced cytokine pro-
duction, e.g. of IL-6, IL-15 and IL-17 [19]. On monocytes,
the expression of Fc receptors I and II (CD64 and CD32) is
decreased, so that the capacity of the monocytes to be activat-
ed by circulating immune complexes is reduced [20].
Destruction of the joint
The production of RANK-L by synovial fibroblasts is de-
creased and that of osteoprotegerin is increased [21]. Both
mechanisms reduce the differentiation of osteoclasts and, as
a consequence, the amount of bone destruction. Methotrexate
also reduces the concentration of MMP-1 and MMP-3 and
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thus could contribute to the preservation of the joint cartilage.
In contrast, angioneogenesis does not appear to be influenced
[22].
Mode of action of the TNF inhibitors
As described above, TNF-α is one of the dominant cytokines
in the pathogenesis of RA. TNF-α is predominantly produced
by monocytes/macrophages, as well as by T cells, and acti-
vates, for example, macrophages and endothelial cells, after
binding to the TNF receptor (CD120), which is expressed on
multiple cells. As a consequence, there is an increase in the
production of IL-1, IL-6 and other proinflammatory cyto-
kines. Due to the important role of TNF-α in the pathophys-
iology of RA, TNF inhibitors are used in therapy. Infliximab is
a chimaeric antibody targeted at TNF-α. Today, complete hu-
man antibodies against TNF-α are available in the form of
adalimumab and golimumab, while certolizumab is a
pegylated human anti-TNF-α antibody (which does not bind
to Fc receptors); etanercept is a soluble TNF receptor. Every-
day clinical experience shows that some RA patients respond
to a second, but not the first, TNF blocker. Therefore, there
may be subtle differences in the modes of action of the indi-
vidual TNF inhibitors, which will not be discussed here in
general, however.
TNF inhibitors influence the pathophysiology of RA on
several levels.
Adhesion/migration
At least in vitro, TNF inhibitors reduce the expression of
VCAM on endothelial cells from the microvasculature of the
intestine [23] and thereby reduce the ability of leucocytes to
migrate from the blood into the inflamed tissue via adhesion to
the vessel walls.
Activation
The degree of activation of the monocytes is markedly re-
duced [24, 25]. In the synovial fluid, the number of neutrophil
granulocytes and myeloid dendritic cells (mDCs) is reduced
during TNF inhibition (Fig. 2).
The influence on lymphocytes is less pronounced. In
vitro studies have shown that infliximab is able to induce
apoptosis (programmed cell death) at least in some T
lymphocytes. In vivo, however, both infliximab and
etanercept were able to trigger apoptosis only in mono-
cytes, but not in lymphocytes [26]. The activity of CD4+
CD25+-regulatory T cells which are involved in the pro-
tection from autoimmune disease is also unaffected [27].
The subpopulations of the B lymphocytes are generally
not affected by TNF inhibitors. The number of memory
B lymphocytes was increased only in the subset of RF-
negative RA patients [28].
The change in cell populations affects the production of
cytokines in the blood. Specifically, the concentration of pro-
inflammatory cytokines produced by monocytes, such as IL-
6, MIP-1 and CCL20 [29], is reduced during treatment with
TNF inhibitors. The concentration of cytokines produced by T
cells, however, does not change [29].
Joint destruction
TNF inhibitors decelerate joint destruction even if the inflam-
mation does not improve. TNF inhibitors reduce the produc-
tion of MMPs (such as MMP-1, MMP-3, MMP-9) that con-
tribute to the chondroclast activation and cartilage destruction
[30]. Furthermore, the production of RANK-L and osteopro-
tegerin (involved with the osteoclast activation and bone de-
struction) is reduced [21, 31]. The production of VEGF, stim-
ulating angiogenesis required for the blood supply of the
pannus tissue, is also reduced [32, 33].
Mode of action of tocilizumab
Tocilizumab binds both to the membrane-bound and soluble
IL-6 receptor and can thus completely interrupt the effect of
IL-6. IL-6 is a proinflammatory cytokine that binds to the IL-6
receptor and then to gp130, a signal transduction molecule.
The membrane-bound IL-6 receptor is only expressed on few
Fig. 1 Immunological targets of
methotrexate
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cell types. However, the soluble IL-6 receptor circulates in the
blood and binds to IL-6. This complex can bind to gp130,
which is expressed on the surface of most cells (trans-signal-
ling). IL-6 therefore has a widespread effect onmany cells and
functions. In the inflammatory process, IL-6 increases the
production of chemokines and expression of adhesion mole-
cules on lymphocytes [34]. The production of chemokines
(such as MCP-1, IL-8) is also increased in endothelial cells,
rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)
and mononuclear cells [35, 36], as is the synthesis of
RANK-L by RA-FLS, and that of MMP-1, MMP-3 and
MMP-13 in chondrocytes [37].
The costimulation of naïve T cells with IL-6 is key to their
differentiation into proinflammatory Th17 cells, which play
an important role in the pathophysiology of RA. IL-6 was
originally identified as a differentiation factor of B cells and
is involved in the development of plasma cells [38]. IL-6 also
acts on plasmablasts and additionally induces the IL-21 pro-
duction of CD4+ T cells [39], which in turn increases the
proliferation of B cells.
Activation
Tocilizumab has a particularly marked effect on the B cells. A
reduction in the number of memory B cells [40, 41] has been
seen in patients with RA and systemic lupus erythematosus
(SLE), along with reductions in plasma cells [42] and in-
creases of the number of regulatory B cells [43] that can in-
terrupt immune reactions (Fig. 3). The number of B cells in the
inflamed synovial membrane is reduced [44]. Tocilizumab
can recover the T cell balance in RA patients as it reduces
the number of Th17 cells and increases the ratio of regulatory
T cells [45]. The concentration of the proinflammatory cyto-
kines [29] produced by the T cells is also reduced. Toci-
lizumab not only acts on lymphocytes but also reduces the
number of monocytes and myeloid dendritic cells in the pe-
ripheral blood of RA patients [46]. Additionally, the number
of neutrophil granulocytes, which represent the majority of
cells in the synovial fluid, is markedly reduced, at least in
the peripheral blood.
Joint destruction
Treatment with tocilizumab reduces VEGF and RANK-L pro-
duction [47] by RA-FLS and thus angiogenesis and activation
of osteoclasts. A reduction in RANK-L has been shown to
increase the number of osteoblasts and reduce that of the os-
teoclasts in a monkey model [48].
A comparison of tocilizumab responders and nonre-
sponders showed that the concentration of macrophage
migration inhibitory factor (MIF), tumour necrosis
factor-like weak inducer of apoptosis (TWEAK) and “C-
X-C motif chemokine 10” (CXCL10) was reduced in re-
sponders [49]. MIF is produced by monocytes and T cells
alike and is involved in the perpetuation of synovitis and
destruction. During therapy with tocilizumab, proinflam-
matory cytokines such as IL-1 and IL-2 produced by T
cells and TNF-α produced by monocytes are also
reduced.
According to current insights, tocilizumab therefore has a
very broad effect and regulates B and T lymphocytes, as well
as the monocytes and dendritic cells.
Fig. 2 Immunological targets of
TNF inhibitors
Fig. 3 Immunological targets of
tocilizumab
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Implications for practice
– TNF inhibitors, whose mode of action (MoA) primarily
targets monocytes and dendritic cells, and MTX, which
inhibits lymphocytes, exert a synergistic therapeutic ef-
fect in RA.
– Tocilizumab has a broader effect than TNF inhibitors and
mainly targets T and B lymphocytes, but also dendritic
cells and monocytes.
– The combination of TNF inhibitors with methotrexate
fills the gap of each substance with regard to the MoA,
while tocilizumab alone has a very broad effect.
– The observation from studies, which show that toci-
lizumab monotherapy is as effective as tocilizumab in
combination with methotrexate, is therefore not
surprising.
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